KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

Gut microbiota signatures associated with KRAS mutations in patients with colorectal cancer (CRC) have been identified by researchers. Their findings suggest that the gut microbes may serve as ...

Avutometinib and defactinib combination shows over one-year median PFS in recurrent LGSOC patients, with notable efficacy in KRAS-mutant and KRAS-wild-type populations. Verastem Oncology plans FDA ...

Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors BI-2493 and BI-2865, both being developed for the treatment of cancer.

Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix ® (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant ...

Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose cancer had progressed after multiple prior lines of therapy The majority of ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject ...